{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang Y"],"funding":["Tianjin Public Health Bureau Foundation","General Hospital of Tianjin Medical University Youth Incubation Foundation","National Science and Technology Program during the Twelfth Five-year Plan Period","Tianjin Municipal Science and Technology Commission Foundation","the National Natural Science Foundation","Shanxi Public Health Bureau Foundation"],"pagination":["797-811"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7242277"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["80(8)"],"pubmed_abstract":["Background
The advantages of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in reducing risk of cardiovascular events (CVEs) and delaying end-stage kidney disease (ESKD) in patients with chronic kidney disease (CKD) is well-known. However, the efficacy and safety of these agents in non-dialysis CKD stages 3-5 patients are still a controversial issue.Methods
Two investigators (Yaru Zhang and Dandan He) independently searched and identified relevant studies from MEDLINE (from 1950 to October 2018), EMBASE (from 1970 to October 2018), and the Cochrane Library database. Randomised clinical trials in non-dialysis CKD3-5 patients treated with renin-angiotensin system (RAS) inhibitors were included. We used standard criteria (Cochrane r"],"journal":["Drugs"],"pubmed_title":["ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials."],"pmcid":["PMC7242277"],"funding_grant_id":["201302051","30800529","14JCYBJC27900","81600553","No. 2011BAI10B02","ZYYFY2015001","81270791","2014KR16"],"pubmed_authors":["Zhang W","Liu Y","He D","Lin S","Guo Y","Zhang Y","Xing Y","Wang F","Yan T","Jia J"],"additional_accession":[]},"is_claimable":false,"name":"ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.","description":"Background
The advantages of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in reducing risk of cardiovascular events (CVEs) and delaying end-stage kidney disease (ESKD) in patients with chronic kidney disease (CKD) is well-known. However, the efficacy and safety of these agents in non-dialysis CKD stages 3-5 patients are still a controversial issue.Methods
Two investigators (Yaru Zhang and Dandan He) independently searched and identified relevant studies from MEDLINE (from 1950 to October 2018), EMBASE (from 1970 to October 2018), and the Cochrane Library database. Randomised clinical trials in non-dialysis CKD3-5 patients treated with renin-angiotensin system (RAS) inhibitors were included. We used standard criteria (Cochrane r","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2025-04-04T22:21:41.679Z","creation":"2020-06-07T07:05:32Z"},"accession":"S-EPMC7242277","cross_references":{"pubmed":["32333236"],"doi":["10.1007/s40265-020-01290-3"]}}